Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C.sub.21H.sub.30O.sub.2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment. Such CBD preparations are characterized by chemical components and/or funtional properties that distinguish them from prior CBD compositions. One or more components of the preparations described herein provide an unexpectedly synergistic effect when utilized in combination.

A method of preparing a Pueraria flower extract rich in isoflavones includes: grinding dry Pueraria flowers to obtain a Pueraria flower powder; adding a first 20-50% ethanol solution to form a mixture, stirring and heating the mixture at 20-80° C. for 1-4 hours, removing the first solution, adding a second 20-50% ethanol solution, stirring and heating the mixture, removing the second solution, and combining the first solution and the second solution to obtain an extract solution; filtering the extract solution to remove solids; concentrating the extract solution under vacuum to obtain a crude extract containing 10-40% solid components; adding anhydrous ethanol solution to reach an ethanol concentration of the crude extract of 75-95%, storing the crude extract at 20-30° C. for 1-4 hours; centrifuging the crude extract at a speed of 2,000-5,000 r/min to obtain a supernatant; and concentrating and spray drying to obtain the Pueraria flower extract without any purification steps.

This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids.

Disclosed is an extract of algae of the order Ulvales, including sulfated and non-sulfated polyanionic polysaccharides, the molecular weight of which is less than or equal to 50 kDa, for use in the prevention and/or treatment of complications caused by post-traumatic immunosuppression.

The present invention relates to a drug for treating leukopenia, its preparation method and use thereof. The drug of the invention is prepared from 200-30 parts by weight of Folium Epimedii, 100-160 parts by weight of Fructus Psoraleae, 60-120 parts by weight of Radix Aconiti Lateralis Preparata (Processed), 200-300 parts by weight of Fructus Lycii, 200-300 parts by weight of Radix Astragali, 200-300 parts by weight of Caulis Spatholobi, 200-300 parts by weight of Radix Rubiae, 100-160 parts by weight of Radix Angelicae Sinensis, 200-300 parts by weight of Rhizoma Phragmitis, 100-160 parts by weight of Radix Ophiopogonis and 100-160 parts by weight of Radix et Rhizoma Glycyrrhizae. The drug of the invention comprises chemical substances with weight ratios as follows: Leucine:guanosine:psoralenoside:isopsoralenoside:calycosin-7-glucoside:liquiritin:icariin A:1,3-dihydroxyl-2-hydroxymethylanthraquinone:epimedin A:epimedin B:epimedin C:icariin:1,3,6-trihydroxy-2-methylanthraquinone:glycyrrhizic acid=(0.13-0.27):(0.04-0.11):(0.11-0.34):(0.09-0.34):(0.05-0.11):(0.16-0.26):(0.09-0.12):(0.17-0.35):(0.11-0.16):(0.17-0.26):(0.49-0.59):1.00:(0.16-0.24):(0.08-0.14).

The present invention discloses an application of litchi chinensis pericarp extract mainly composed of polymer polyphenols in preparation of α-amylase inhibitor, which belongs to the technical field of biology. The litchi chinensis pericarp extract mainly composed of polymer polyphenols disclosed by the present invention has a very good inhibitory effect on α-amylase, whereas α-amylase is applied in weight and blood glucose reduction, biological pesticides, dental caries prevention, and osteoporosis prevention and treatment.

A method for drying to increase the useful life of botanicals and shorten the time to market after harvest of the botanicals. The method may include flash freezing the botanicals, at a desired optimal temperature range, soon after harvest. The method may include storing the frozen botanicals indefinitely prior to drying. The method may include drying the frozen botanicals using a lyophilizer at a desired optimal temperature and pressure.

A Ganoderma lucidum polysaccharides composite composition comprising, based on a total composition: 1 to 5 wt. % β-glucan extract, 1 to 5 wt. % Ganoderma lucidum mycelium extract, 1 to 5 wt. % Trametes versicolor mycelium extract, 1 to 5 wt. % Tremella fuciformis Berk extract, 1 to 5 wt. % Auricularia auricula-judae extract, 1 to 5 wt. % Hericium erinaceus extract, 1 to 3 wt. % Ganoderma lucidum fruiting body extract, and water.

The invention provides to an enriched Withania somnifera (Ashwagandha) extract composition comprising withanolide glycosides, withanolide aglycones and reduced levels of withaferin-A. The invention also provides to process for the preparation of these compositions and further provides to methods of improving testosterone levels, energy levels, sustained energy, vigor, stamina, and muscle mass and muscle strength using these compositions.

The present disclosure relates to a composition comprising a Salvia miltiorrhiza Bunge extract as an active ingredient for treatment or prevention of benign prostatic hyperplasia or alopecia, the Salvia miltiorrhiza Bunge extract being characterized by containing tanshinones in 2-70%, including tanshinone1, tanshinone2a, cryptotanshinone, and dihydrotanshinone, and can provide a pharmaceutical composition and a health functional food for treatment or prevention of alopecia and benign prostatic hyperplasia.